Drug intelligence / Profile preview

Effiprev

Development stage
Unknown
Lead developer
Effik
Modality
Small Molecules
Administration
Oral
01

Overview

Effiprev is a combined oral contraceptive (COC) marketed by Effik Italia. It is a fixed-dose combination of the synthetic progestin dienogest (2 mg) and the synthetic estrogen ethinylestradiol (0.03 mg). Effiprev is primarily indicated for oral contraception and for the treatment of moderate acne in women who choose to use an oral contraceptive after the failure of suitable topical therapies or oral antibiotics. Dienogest acts as an agonist of the progesterone receptor and exhibits antiandrogenic activity by antagonizing the androgen receptor, which helps improve acne. Ethinylestradiol acts as an agonist of the estrogen receptor, stabilizing the uterine lining and working synergistically with dienogest to suppress the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation.

Brand names
AglaeAmgestCemisianaCestel 30Cestel30Cestel-30DailyprevDienilleDienogenDienotyco-ETDraptonic-EEffiprevEstro PlusFreedaseJeanineKelseeNovadienSerisimaSibillaSibilletteSiluetteValette
Other names
dienogest + ethinylestradioldienogest/ethinylestradiolethinylestradiol + dienogestethinylestradiol/dienogest
02

Targets

PR (Progesterone receptor)ESR2 (ERβ)AR (Adrenergic receptors)ESR1 (ERα)

Beyond the preview

Go deeper on Effiprev.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Effiprev.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call